Posts with or without credits tagged 'novartisnews'
- 89 posts
- 3.5k likes
- 1.1k shares
- 147 comments
On Thursday, July 17 Novartis will announce its Q2 2025 earnings. Register to listen here: t.co/OxvoXsInQI
#NovartisNews $NVS $NOVN #NVSQ22025
12
2
4
12
2
4
14
3
5
14
3
5
On Friday, January 31 Novartis will announce its Q4 and Full-Year 2024 results. Register to listen here: t.co/qRmJZD5Y8k
#NovartisNews $NVS $NOVN #NVSQ424
16
3
3
16
3
3
Novartis delivered a very strong quarter, with double-digit sales and core operating income growth leading to a further upgrade to 2023 guidance.
#NovartisNews $NVS $NOVN #NVSQ323
222
32
17
222
32
17
Breaking News: Novartis announces intention to separate Sandoz business to create a standalone company.
Planned 100% spin-off provides potential future upside of both Sandoz and Novartis Innovative Medicines.
#NovartisNews $NVS $NOVN
32
12
1
32
12
1
#BreakingNews: Novartis receives FDA priority review for investigational biologic therapy for the prevention of #sicklecell disease pain crises. #NovartisNews Read more here: t.co/cae6Si7G6Z
96
38
5
96
38
5
At #EAN2019 we are highlighting cognition data in SPMS. We are committed to improving the lives of people living with Secondary Progressive MS #ReimagineMedicine #NovartisNews
14
6
1
14
6
1
#NovartisNews: We’ve successfully completed our acquisition of the only Rx approved to treat both signs and symptoms of #dryeyedisease with anti-inflammatory properties, strengthening industry-leading #eyecare ophthalmic pharmaceuticals business. t.co/bWvIncifrD
39
9
3
39
9
3
Today we are presenting #migraine data at #EAN2019 on new facets important in the lives of #migraine patients. #NovartisNews #PreventiveTherapies Read more here: t.co/CxzepOLJRP
20
5
2
20
5
2
Today we are at #EAN2019 presenting results in #migraine reinforcing the long-term breadth of data for patients who failed prior #PreventiveTreatment. #NovartisNews #ReimagineMedicine
14
6
1
14
6
1
Breaking at #EHA24: Novartis presents new data on potential treatments for chronic myeloid leukemia (CML) #NovartisNews #reimaginemedicine
23
12
4
23
12
4
BREAKING: New Phase III data on biologics and the inhibition of psoriatic arthritis disease progression. Learn more: t.co/wekhkt1w6X #NovartisNews
33
5
3
33
5
3
#NovartisNews: Novartis announces new data on efficacy of a biologic in the management of axial manifestations of #PsoriaticArthritis t.co/ceeJrWEjFZ
19
1
3
19
1
3
BREAKING: Five-year analysis of our targeted therapy in advanced melanoma presented at #ASCO19. Learn more at t.co/j5mggVKYrf #NovartisNews.
39
16
2
39
16
2
BREAKING at #ASCO19: New data from a Phase II trial of our investigational MET inhibitor for advanced lung cancer. Learn more at t.co/QqLwEZOFTv #NovartisNews.
54
16
3
54
16
3
14
2
14
2
BREAKING: Novartis announces #overallsurvival results for its CDK4/6 inhibitor to treat premenopausal #advancedBC at @ASCO #NovartisNews
90
37
90
37
#NovartisNews: First phase III data of new investigational inhaled asthma treatment t.co/JTMo7Q5wPP
29
6
1
29
6
1
BREAKING: Novartis receives FDA approval for a new treatment of HR+/HER2- advanced or metastatic breast cancer with a mutation. #NovartisNews
242
85
10
242
85
10
Novartis unveils first phase II data of new #asthma treatment delivered with dose-confirming Breezhaler at #ATS19 #NovartisNews t.co/MvAy0DTXKi
32
6
1
32
6
1
#NovartisNews 100+ abstracts for the most difficult-to-treat cancers and blood disorders at #ASCO19 and #EHA24 #ReimagineMedicine t.co/vo1JdeqDWz
21
5
21
5
#NovartisNews: For the first time, Novartis presents full data from head-to-head Phase III study in relapsing remitting #MS being presented at #AANAM2019 #reimaginemedicine t.co/qRQ4nVEbH4
23
6
23
6
#NovartisNews: Novartis to acquire only Rx approved to treat both signs and symptoms of #dryeyedisease with anti-inflammatory properties, strengthening industry-leading #eyecare ophthalmic pharmaceuticals business
15
1
15
1
#NovartisNews: New cognition data from Phase III Secondary Progressive #MS trial being presented at #AANAM2019 #reimaginemedicine
17
4
17
4
18
3
1
18
3
1
SIGN UP FOR FREE TO KEEP EXPLORING! 🔐
To access more than the first page of results, sign in or sign up for an account!